OFI Invest Asset Management Invests $33,000 in Humana Inc. (NYSE:HUM)

OFI Invest Asset Management acquired a new position in Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 135 shares of the insurance provider’s stock, valued at approximately $33,000.

Other institutional investors have also made changes to their positions in the company. FPC Investment Advisory Inc. acquired a new position in Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the fourth quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in Humana during the third quarter worth $31,000. Atwood & Palmer Inc. increased its holdings in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new position in Humana during the fourth quarter worth $49,000. Institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.32% of the stock is currently owned by company insiders.

Humana Trading Down 0.4 %

HUM stock opened at $250.21 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company’s 50-day simple moving average is $271.67 and its 200 day simple moving average is $281.65. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a market capitalization of $30.19 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.41%. Humana’s dividend payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. Barclays upped their price objective on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Finally, Morgan Stanley decreased their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.